Search alternatives:
mean decrease » a decrease (Expand Search)
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
Showing 401 - 420 results of 30,130 for search '(( 5 ((ng decrease) OR (mean decrease)) ) OR ( 50 ((we decrease) OR (nn decrease)) ))', query time: 0.70s Refine Results
  1. 401
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 402
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 403
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 404
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 405
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 406
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 407
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 408
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 409
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 410
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 411
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 412
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 413
    Type and duration of leisure-time activities performed 5 years after RYGB.

    Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

    Published 2022
    Save to List
    Saved in:
  14. 414
    Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst.

    Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. by Jian Hao (160736)

    Published 2013
    Save to List
    Saved in:
  15. 415
    AA-deficient <i>sfx</i> mice had decreased articular cartilage.

    AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

    Published 2019
    Save to List
    Saved in:
  16. 416
    <b>Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons</b>

    <b>Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons</b> by Muhammad Saad Yousuf (20745168)

    Published 2025
    Save to List
    Saved in:
  17. 417
    Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months.

    Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months. by Allyson J. Gallant (9382396)

    Published 2021
    Save to List
    Saved in:
  18. 418
    E<sub>50</sub> values of angle.

    E<sub>50</sub> values of angle. by Junxia Zhou (14381598)

    Published 2024
    Save to List
    Saved in:
  19. 419
    Curve fitting of E<sub>50</sub>.

    Curve fitting of E<sub>50</sub>. by Junxia Zhou (14381598)

    Published 2024
    Save to List
    Saved in:
  20. 420
    Fitting curves of E<sub>50</sub>.

    Fitting curves of E<sub>50</sub>. by Junxia Zhou (14381598)

    Published 2024
    Save to List
    Saved in:

Search Tools: